期刊文献+

厄贝沙坦、氢氯噻嗪联合治疗原发性高血压的疗效观察 被引量:2

下载PDF
导出
摘要 目的观察厄贝沙坦和氢氯噻嗪联合治疗原发性高血压的疗效和安全性。方法将120例18岁以上的原发性高血压患者随机分为两组,治疗组给予厄贝沙坦150mg+氢氯噻嗪(安博诺),1次/d,对照组采用氨氯地平片,5mg/d,疗程为6周,观察两组的疗效。结果治疗组总有效率为88.3%,对照组总有效率为75.0%,两组比较差异有统计学意义(P<0.05);与治疗前比较,两组治疗后收缩压、舒张压均明显下降,差异有统计学意义(P<0.01);治疗组血压达标率为71.7%,对照组血压达标率为61.7%,两组比较差异有统计学意义;两组均无因不良反应而中断治疗的患者。结论厄贝沙坦联合小剂量氢氯噻嗪治疗原发性高血压疗效确切,治疗6周达标疗效显著,患者依从性好,不良反应发生率低。
作者 阮宾
出处 《中国当代医药》 2012年第12期38-39,共2页 China Modern Medicine
  • 相关文献

参考文献6

二级参考文献19

  • 1刘力生.2004年中国高血压防治指南(实用本)[J].中华心血管病杂志,2004,32(12):1060-1064. 被引量:2620
  • 2Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension : analysis of worldwide data[J]. Lancet,2005,365:217-223.
  • 3World Health Organization. The world health report 2002. Reducing risks, pro- moting healthy life[ M]. Geneva: World Health Organization. 2002.
  • 42007 ESH Guidelines for the Management of Hypeitension[J]. J Hypertens, 2007,25: 1105-1118.
  • 5Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004 [ J ]. Hyperten- sion ,2007,49:69-75.
  • 6Gradman AH, Basile JN, Barry L,et al. Combination therapy in hypertension [ J]. J Am Soc Hypertens,2010,4( 1 ) :42-50.
  • 7Stanton T, Reid JL. Commentary-fixed dose combination therapy in the treat- ment of hypertension[ J]. J Hum Hypertens,2002,16(2) :75-78.
  • 8George LB, Pantelis AS, Matthew RW. Renal outcomes with different fixed- dose combination therapies in patients with hypertension at high risk for cardio- vascular events (ACCOMPLISH) : a prespecified secondary analysis of a randomised controlled trial[ J ]. Lancet ,2010,375 : 1173-1181.
  • 9Neutel JM, Saunders E, Bakris GL, et al. The efficacy and safety of low- and high- dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: The INCLUSIVE Trial [J]. J Clin Hypertens,2005,7(10) :578-586.
  • 10Zappe D, Papst CC, Philippe F. Randomized study to compare valsartan ±HCTZ versus amlodipine ± HCTZ strategies to maximize blood pressure control [J]. Vasc Health Risk Manag ,2009,5: 883-892.

共引文献390

同被引文献25

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部